Last $20.87 USD
Change Today -0.06 / -0.29%
Volume 901.4K
OMER On Other Exchanges
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

omeros corp (OMER) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/2/15 - $25.84
52 Week Low
05/21/14 - $9.76
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for OMEROS CORP (OMER)

omeros corp (OMER) Related Bloomberg News

View More Bloomberg News

omeros corp (OMER) Related Businessweek News

No Related Businessweek News Found

omeros corp (OMER) Details

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes products targeting inflammation, coagulopathies, and disorders of the central nervous system. Its clinical products include Omidria, which has completed two Phase III clinical trials for use during intraocular lens replacement, including cataract and other lens replacement surgery; OMS103 that is in Phase III clinical program for use during arthroscopic procedures, such as partial meniscectomy surgery; and OMS824, which is in Phase II clinical trial for the treatment of CNS disorders comprising schizophrenia and Huntington's disease. Its clinical programs also consist of OMS721 that is in Phase II clinical trial for the treatment of various complement-related diseases and disorders, including thrombotic microangiopathies; OMS405, which is in Phase II clinical trial for the treatment and prevention of addiction to substances of abuse; and OMS201 that has completed Phase 1/Phase 2 clinical trial for use during urological procedures, such as ureterscopy for removal of ureteral or renal stones. The company’s preclinical products and development programs comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders, such as Parkinson's disease; and OMS616 for the control of blood loss during surgery, or resulting from trauma or other hyperfibrinolytic conditions. Its preclinical products also include G protein-coupled receptors platform for multiple disorders across therapeutic area; GPR17 for demyelinating disorders; and antibody platform for the discovery of monoclonal antibodies. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.

75 Employees
Last Reported Date: 03/13/14
Founded in 1994

omeros corp (OMER) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $664.6K
Principal Financial Officer, Chief Accounting...
Total Annual Compensation: $79.7K
Vice President of Patent, General Counsel and...
Total Annual Compensation: $342.5K
Compensation as of Fiscal Year 2013.

omeros corp (OMER) Key Developments

Omeros Corporation's Phase 2 OMS721 Trial Resulting in Extended Access for Compassionate Use

Omeros Corporation announced that it has completed dosing of the low-dose cohort of patients in its ongoing Phase 2 clinical trial evaluating the efficacy and safety of OMS721, the lead human monoclonal antibody for its mannan-binding lectin-associated serine protease-2 (MASP-2) program, in treating thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) in the microcirculation of the body's organs, most commonly the kidney and brain. All patients in this study cohort received OMS721 and improvements were observed across TMA disease markers. The investigators treating all of these patients at different sites consider the improvements to be treatment-related and clinically meaningful. Based on observations in this cohort, a European investigator has requested that Omeros provide extended access to OMS721 for compassionate use in his two study patients, both of whom suffer from atypical hemolytic uremic syndrome (aHUS), a form of TMA. In the clinical trial, the first cohort consisted of three patients treated with the lowest dose of OMS721. All three patients have aHUS. Platelet count, serum lactate dehydrogenase (LDH), and serum haptoglobin were measured as markers of disease activity. When compared to baseline levels, platelet counts improved in all patients. Serum LDH levels remained normal in one patient, substantially decreased to close to the normal range in another and remained elevated in the third. Haptoglobin improved in two patients, normalizing in one. Creatinine levels in the one patient with independent renal function also improved. Under this program of extended access, the two patients treated by the investigator requesting compassionate use will continue to undergo current or higher dosing with OMS721. The third patient, treated at a site other than that of the requesting investigator, appeared clinically to no longer be in the acute phase of the disease after treatment with OMS721. The patient subsequently relapsed following cessation of OMS721 treatment. This patient was discontinued from the trial for precautionary reasons because of a serious adverse event – a localized inflammatory response often related to certain types of infections, one of which the patient previously had for three years while on immunosuppressive therapy. Such infections are associated with widely used TNF-alpha-targeting drugs. All data to date indicate no active infection in this patient. No other significant safety issues were observed in either this trial or in the previously completed Phase 1 program. Consistent with the Phase 2 trial protocol, a pre-planned data review by internal and external physicians resulted in a recommendation to proceed with the planned dose escalation to the mid-dose cohort.

Omeros Seeks Acquisitions

Omeros Corporation (NasdaqGM:OMER) has filled an Offering. Omeros said, "We intend to use the net proceeds from this offering for general corporate purposes, including expenses related to the commercialization of Omidria, research and development expenses, such as funding clinical trials, pre-clinical studies, manufacturing development and costs associated with otherwise advancing our drug candidates toward New Drug Application submission. We may also use the net proceeds for working capital, the repayment of debt obligations, acquisitions or investments in businesses, products or technologies that are complementary to our own, and other capital expenditures."

Omeros Seeks Acquisitions

Omeros Corporation (NasdaqGM:OMER) is seeking acquisitions. Omeros Corporation has filed a Shelf Registration, the proceeds of which will be used for working capital, the repayment of debt obligations, acquisitions or investments in businesses, products or technologies.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OMER:US $20.87 USD -0.06

OMER Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OMER.
View Industry Companies

Industry Analysis


Industry Average

Valuation OMER Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,344.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,366.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OMEROS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at